Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review.

Oncology research and treatment - 1 Jan 2022

Wang Liye, Lu Qianyi, Jiang Kuikui, Hong Ruoxi, Wang Shusen, Xu Fei

Abstract excerpt

BACKGROUND: The B-Raf proto-oncogene (BRAFV600E) gene mutation has been identified in a variety of malignancies, but no evidence of the efficacy of vemurafenib treatment in BRAFV600E mutant breast cancer (BC) has been reported. CASE PRESENTATION: We reported a 60-year-old woman with confirmed triple-negative BC with BRAFV600E mutation. Progression-free survival (PFS) for first-line chemotherapy was 7 months. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Cancer Treatment Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Melanoma and MAPK Pathways

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Triple Negative Breast Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 34818649
DOI: 10.1159/000520453
PMCID: PMC8985016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E Mutation in Triple-Negative Breast Cancer: A Case Report and Literature Review.PMID 34818649Read ↗

Vemurafenib.Semantic proximity Read ↗

Efficacy of MEK inhibitors in Erdheim-Chester disease: impact of MAPK pathway pathogenic variantsSemantic proximity Read ↗

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.Semantic proximity Read ↗

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation.Semantic proximity Read ↗

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.Semantic proximity Read ↗

A patient with malignant pleural mesothelioma carrying BRAF V600E mutation responding to vemurafenib.Semantic proximity Read ↗

FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation.Semantic proximity Read ↗

Cobimetinib Plus Vemurafenib: A Review in BRAF (V600) Mutation-Positive Unresectable or Metastatic Melanoma.Semantic proximity Read ↗

Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.Semantic proximity Read ↗

The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.Semantic proximity Read ↗

BRAF-mutated clear cell sarcoma is sensitive to vemurafenib treatment.Semantic proximity Read ↗

Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.